Griseofulvin suspension

Griseofulvin suspension

Form: Suspension

Strength: 50 mg/5 mL; 125mg/5ml

Reference Brands: Grifulvin V(US); Griséofulvine(EU)

Category: Anti-fungal

Griseofulvin suspension is approved in the EU and US for treating dermatophyte infections in children and adults. In the EU, various generic formulations are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval for generic versions is based on comprehensive data and biosimilarity assessments. Both regions require detailed dossiers for initial approval and ongoing pharmacovigilance. For expert assistance with pharmaceutical dossiers, regulatory submissions, and compliance, visit PharmaTradz. We facilitate smooth market access for griseofulvin suspension, ensuring adherence to European and American standards for safe, effective dermatophyte treatment.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Nystatin Oral Suspensions/Tablets

Strength: Tab: 500,000 units, 1,000,000 units; Sus: 100,000 units/mL, 500,000 units/5 mL

Form: Tablets/Suspensions

Reference Brands: Mycostatin, Nilstat, Nystop(US)

View Details Get Enquiry
Nystatin Topical Creams and Ointments

Strength: 100,000 units/g, 100,000–300,000 units/g

Form: Topical Creams and Ointments

Reference Brands: Mycostatin, Nilstat, Nystop(US)

View Details Get Enquiry
Micafungin Intravenous (IV) Powder

Strength: 50 mg, 100 mg/vial

Form: Intravenous (IV) Powder

Reference Brands: Mycamine(US & EU)

View Details Get Enquiry
Anidulafungin injection

Strength: 50 mg/vial

Form: Intravenous (IV) Powder

Reference Brands: Eraxis(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.